Building Strength in Biotech - Equity Research on Arena Pharmaceuticals, Inc. and Rigel Pharmaceuticals, Inc.

HONG KONG, Jun 13 (MARKET WIRE) --
Today, www.WorldStreetFundamentals.com released its industry report
highlighting Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Rigel
Pharmaceuticals, Inc. (NASDAQ: RIGL). Full fundamental and technical
analysis is available at www.WorldStreetFundamentals.com/Reports.php.

This sector demonstrates renewed investor interest as new and lucrative
therapies come to market. The FDA approved the first new drug in 50 years
to treat auto-immune disorder lupus in March 2011, and we expect approval
of new treatments for Hepatitis C virus around mid-year. The 2010 health
care reform act authorized the FDA, will establish a regulatory pathway
for approving "biosimilar" drugs, which in turn will increase production
and shorten FDA approval times.

Longer term, it is expected that a wider acceptance of biomarker research
and genetic-targeted clinical studies to help limit expense. It is viewed
that therapeutics for cancer and infectious diseases and autoimmune and
inflammatory treatments are primary growth areas.

World Street Fundamentals has highlighted Arena Pharmaceuticals, Inc. as
a clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing oral drugs that target G protein-coupled
receptors (GPCRs), in four major therapeutic areas: cardiovascular,
central nervous system, inflammatory and metabolic diseases. On May 26,
2011 they presented meta-analyses of the three trials in the lorcaserin
Phase 3 clinical trial program at ECO 2011, the 18th European Congress on
Obesity. The entire report on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)
is available here: www.WorldStreetFundamentals.com/ViewFullReport.245.php.

World Street has featured Rigel Pharmaceuticals, Inc. (Rigel), as it is a
clinical-stage drug development company. The Company discovers and
develops small-molecule drugs for the treatment of
inflammatory/autoimmune diseases, as well as for certain cancers and
metabolic diseases. The Company has product development programs in
inflammatory/autoimmune diseases, such as rheumatoid arthritis,
thrombocytopenia and asthma, as well as in cancer. The entire report on
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is available here:
www.WorldStreetFundamentals.com/ViewFullReport.138.php.

About World Street
World Street Fundamentals is an online portal for
professionals, investors and new-comers to the markets to find in depth
comprehensive research and research tools to help guide you through the
ever changing financial markets. Covering the top performers in the
hottest sectors and providing clarity to investors around the world.

Contact:

Adam Redford
editor@worldstreetfundamentals.com
www.WorldStreetFundamentals.com

Copyright 2011, Market Wire, All rights reserved.

-0-